Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.
Annals of Hematology.
Times cited: 10
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): A randomised, controlled, phase 3 trial.
The lancet oncology.
Times cited: 34
Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?.
American Journal of Hematology.
Times cited: 9